M. Jasińska-Stroschein

发表

Concomitant Administration of Different Doses of Simvastatin with Ivabradine Influence on PAI-1 and Heart Rate in Normo- and Hypercholesterolaemic Rats

J. Owczarek, M. Jasińska-Stroschein, D. Orszulak-Michalak, 2012, TheScientificWorldJournal.

The differential effects of neuroleptic drugs and PACAP on the expression of BDNF mRNA and protein in a human glioblastoma cell line.

E. Kowalczyk, M. Jasińska-Stroschein, M. Jóźwiak-Bębenista, 2017, Acta neurobiologiae experimentalis.

Searching for an experimental rodent model of heart failure with preserved ejection fraction: Re-visited.

M. Jasińska-Stroschein, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Animal models of pulmonary arterial hypertension: A systematic review and meta‐analysis of data from 6126 animals

M. Jasińska-Stroschein, K. Sztuka, 2017, Pharmacological research.

Toward Better Reproducibility in Experimental Research on New Agents for Pulmonary Hypertension. An Analysis of Data from Four Hundred Animal Studies

M. Jasińska-Stroschein, 2020, Cardiovascular Drugs and Therapy.

A review of genetically-driven rodent models of pulmonary hypertension.

M. Jasińska-Stroschein, 2022, Vascular pharmacology.

The Effectiveness of Pharmacist Interventions in the Management of Patient with Renal Failure: A Systematic Review and Meta-Analysis

M. Jasińska-Stroschein, 2022, International journal of environmental research and public health.

Errors in reporting on dissolution research: methodological and statistical implications

M. Jasińska-Stroschein, D. Orszulak-Michalak, U. Kurczewska, 2017, Pharmaceutical development and technology.

HMG-COA reductase inhibitors: An opportunity for the improvement of imatinib safety. An experimental study in rat pulmonary hypertension

J. Owczarek, M. Jasińska-Stroschein, D. Orszulak-Michalak, 2015, Pharmacological reports : PR.

Concurrent Rho-Kinase and Tyrosine Kinase Platelet-Derived Growth Factor Inhibition in Experimental Pulmonary Hypertension

J. Owczarek, M. Jasińska-Stroschein, D. Orszulak-Michalak, 2014, Pharmacology.

A review of rodent models for metabolic syndromes and pulmonary hypertension.

M. Jasińska-Stroschein, 2021, Toxicology and applied pharmacology.

Training programs in preclinical studies. The example of pulmonary hypertension. Systematic review and meta-analysis

M. Jasińska-Stroschein, 2022, PloS one.

The background and new perspectives and agricultural aspects concerning food allergy and fruit hypersensitivity

J. Owczarek, M. Jasińska-Stroschein, D. Orszulak-Michalak, 2012 .

The Assessment Of The Risk Of Allergenicity Of ‘Sabina’ And ‘Debreceni Bötermö’ Sour Cherry Cvs (Prunus Cerasus L.) In A Guinea Pig Model

J. Markowski, J. Owczarek, M. Jasińska-Stroschein, 2014 .

An assessment of the risk of allergenicity associated with selected strawberry cultivars on a guinea pig model*

J. Markowski, J. Owczarek, M. Jasińska-Stroschein, 2020 .

Involvement of vascular endothelial growth factor (VEGF) and mitogen-activated protein kinases (MAPK) in the mechanism of neuroleptic drugs

E. Kowalczyk, M. Jasińska-Stroschein, M. Jóźwiak-Bębenista, 2018, Pharmacological reports : PR.

A PHARMACIST CARE PROGRAM: THE POSITIVE IMPACT ON THE OUTCOMES OF LIPID-LOWERING THERAPY

M. Jasińska-Stroschein, 2022 .

Pharmacy students’ beliefs in popular myths about health and therapy

M. Jasińska-Stroschein, D. Orszulak-Michalak, U. Kurczewska, 2020, Health Education Journal.

Rosuvastatin, Sildenafil and Their Combination in Monocrotaline-Induced Pulmonary Hypertension in Rat

J. Owczarek, M. Jasińska-Stroschein, D. Orszulak-Michalak, 2014, Acta pharmaceutica.

Comparative tolerability of targeted therapies in pulmonary hypertension

M. Jasińska-Stroschein, D. Orszulak-Michalak, A. Stępień, 2020, Archives of medical science : AMS.

The Beneficial Impact of Fasudil and Sildenafil on Monocrotaline-Induced Pulmonary Hypertension in Rats: A Hemodynamic and Biochemical Study

J. Owczarek, M. Jasińska-Stroschein, D. Orszulak-Michalak, 2013, Pharmacology.

The current approach into signaling pathways in pulmonary arterial hypertension and their implication in novel therapeutic strategies

M. Jasińska-Stroschein, D. Orszulak-Michalak, 2014, Pharmacological reports : PR.

Title: TREATMENT WITH PLATELET-DERIVED GROWTH FACTOR (PDGF) AND ROCK INHIBITORS IS RELATED TO DECLINED NERVE GROWTH FACTOR (NGF) SIGNALING IN AN EXPERIMENTAL MODEL OF RAT PULMONARY HYPERTENSION

M. Jasińska-Stroschein, D. Orszulak-Michalak, Katarzyna Oszajca, 2017 .

Novel mechanistic and clinical implications concerning the safety of statin discontinuation

J. Owczarek, M. Jasińska-Stroschein, D. Orszulak-Michalak, 2011, Pharmacological reports : PR.

Application of animal models in experimental medicine on the basis of pulmonary hypertension

M. Jasińska-Stroschein, D. Orszulak-Michalak, K. Sztuka, 2018, Postępy Higieny i Medycyny Doświadczalnej.

Multidimensional Interventions on Supporting Disease Management for Hospitalized Patients with Heart Failure: The Role of Clinical and Community Pharmacists

M. Jasińska-Stroschein, Magdalena Waszyk-Nowaczyk, 2023, Journal of clinical medicine.

Statistical Considerations Concerning Dissimilar Regulatory Requirements for Dissolution Similarity Assessment. The Example of Immediate-Release Dosage Forms.

M. Jasińska-Stroschein, D. Orszulak-Michalak, U. Kurczewska, 2017, Journal of pharmaceutical sciences.

Systematic review and meta-analysis of interventions tested in animal models of pulmonary hypertension.

M. Jasińska-Stroschein, D. Orszulak-Michalak, K. Sztuka, 2018, Vascular pharmacology.

Treatment with platelet-derived growth factor (PDGF) and rock inhibitors is related to declined nerve growth factor (NGF) signaling in an experimental model of rat pulmonary hypertension.

M. Jasińska-Stroschein, D. Orszulak-Michalak, Katarzyna Oszajca, 2017 .

Rosuvastatin intensifies the beneficial effects of rho-kinase inhibitor in reversal of monocrotaline-induced pulmonary hypertension

J. Owczarek, M. Jasińska-Stroschein, D. Orszulak-Michalak, 2015, Archives of medical science : AMS.

Novel strategies for treatment of pulmonary arterial hypertension.

M. Jasińska-Stroschein, D. Orszulak-Michalak, 2017, Postępy Higieny i Medycyny Doświadczalnej.

HMG-COA reductase inhibitors: An opportunity for the improvement of imatinib safety. An experimental study in rat pulmonary hypertension

J. Owczarek, M. Jasińska-Stroschein, D. Orszulak-Michalak, 2015 .

Searching for Effective Treatments in HFpEF: Implications for Modeling the Disease in Rodents

M. Jasińska-Stroschein, 2023, Pharmaceuticals.

The Beneficial Impact of Fasudil and Sildenafil on Monocrotaline-Induced Pulmonary Hypertension in Rats: A Hemodynamic and Biochemical Study

J. Owczarek, M. Jasińska-Stroschein, D. Orszulak-Michalak, 2013, Pharmacology.

The current state of preclinical modeling of human diabetic cardiomyopathy using rodents.

M. Jasińska-Stroschein, 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Treatment with platelet-derived growth factor (PDGF) and rock inhibitors is related to declined nerve growth factor (NGF) signaling in an experimental model of rat pulmonary hypertension

M. Jasińska-Stroschein, D. Orszulak-Michalak, Katarzyna Oszajca, 2017, Pharmacological reports : PR.

Innovative Approaches to Enhance and Measure Medication Adherence in Chronic Disease Management: A Review

M. Jasińska-Stroschein, Magdalena Waszyk-Nowaczyk, T. Osmałek, 2024, Medical science monitor : international medical journal of experimental and clinical research.

Improving the treatment of bacterial infections caused by multidrug-resistant bacteria through drug repositioning

M. Jasińska-Stroschein, Paulina Glajzner, Paulina Glajzner, 2024, Frontiers in pharmacology.

Reporting Experimental Studies on Animals - The Problems with Translating of Outcomes to Clinical Benefits. Methodological and Statistical Considerations: The example of Pulmonary Hypertension.

M. Jasińska-Stroschein, D. Orszulak-Michalak, 2021, European journal of pharmacology.